<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 130 - MIMS April 2020 E4</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page129.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../MIMS April 2020 E4.html#p=130">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 130 - MIMS April 2020 E4</div>
        <div id="content-top2">P. 130</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../MIMS April 2020 E4.html#p=130"><img src="../thumb/130.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>Cardio-Vascular Agents - 7.3.3 / 7.3.4                                          2020-04 / 99
       Special precautions: Do not withdr.abrupt.in esp.ischaem.heart   Elderly: 12,5 mg once dly. If inadeq.it may be incr. as tolerat.at 2   Special precautions: Adeq.contr.CHF pts., 1st contr. phaechromo-
       dis., at least 48 hrs.to elapse betw.last dos.& surg.if ther.to be with-  wkly interv.up to 25 mg once dly/in div.dos.   cyt.adeq.with alpha-adrenocept. block., ren.impairm., monit.digoxin
       dr.bef. anaesth., dur.anaesthes., maint.usual dos.peri-op., tachy-  CHF: Admin.concom.with std.ther.Take with food. Indiv. Adults:   lev.when ther. init./adjust./discont., reg.bld.gluc.monit.with insul./oral
       card.respons.poss.obscur., diab.mellit.as hypoglycaem.S&S.poss.  Init.3,125 mg 2xdly x2 wks.incr.to 6,25 mg 2xdly for 2 wks. Maint: 25   hypoglycaem., monit.pts.on concom. meds.lead.to catecholamine de-
               st
       mask., strict fast., 1  degr. AV block, Prinzmetal’s ang., hypovolaem.,   mg 2xdly.in pts. &lt;85 kg (max.dos.) incr.to 50 mg 2xdly in those &gt;85   plet./adrenerg. block. agents, excret.in breast milk, elderly, cirrhos.,
       accomp. HF of any degree, condit.worsen in psorias./hist. therof,   kg (max.dos.) Allow interv.of 2 wks.aft.each dos.incr. Should treatm.  incr.diuret.dos./poss.decr.or discont. Carvedilol Unicorn in case of
       alpha-adrenerg.block.pre-treatm.usual. reqd. in phaeochromocy-  be discont.reinst.ther.at 3,125 mg 2xdly.for 2 wks.& incr.as above.  worsen.card. effs./ fluid retent.dur.dos.incr., pts.controll.on diurets./
       toma, protect expos.areas from sun/UVA light if photosens.react.  Contraindications: Bronchosp., asthma, obstruct. airways dis.hist.,   digital./& ACE inhibits., decr.dos.if pulse rate bel.55 bpm, decr.ther.
       occur, sev. dysrhythm.developm.poss.esp.torsade de pointes result.  bronchit., chron.resp.dis., 2nd/3rd degr.AV block, sev.bradycard.(&lt;50/   grad.in pts.with ischaem. heart dis., diabet.mellit.in CHF esp.dur.ther.
       from hypokalaem., monit.ser.electrol./lipids/ uric acid/bld.gluc.dur.  min.), New York Heart Assoc.class IV decompen. HF requir.IV ino-  init. dos.adjustm., monit.bld.gluc., outweigh benef./risk in pts.not re-
       longt.ther., incr.gout attack risk in hyperuricaem., poss.metabol.al-  trop.support, cardiogen.shock, sick-sinus syndr. incl.sino-arter.block,   quir.oral/inhal.treatm.for bronchosp. dis.& monit.esp.dur.ther.init.&
       kalos. worsen., cholelithias., clonidine transf., withdr. grad., pts.to   hepat.funct. impairm., metabol.acidos., periph.vasc.dis., Raynaud’s   dos.adjustm., thyrotoxicos., Raynaud’s dis., cont.lens., periph. vasc.
       limit phys.activ.dur.withdr.per., poss. life-threat.reacts.with concom.  phenom., sev.hypotens., allerg.condits.involv. airways, pregn. & lac-  dis., Prinzmetal’s ang.esp.dur.ther.init., IV atropine for vagal influence
       hypoglycaem. agents/ phenothiaz./var.anti-dysrhythm.agents, ren./  tat., safety & effic.in childr. not est., safety dur.longt.treatm.not est.,   protect., discont.ther. at least 24 hrs.bef.anaesthes., clonidine transf.
       liv.funct.impairm., incr.rebound hypertens risk with abrupt withdr.of   concom. anaesth. agents caus.myocard.depress., cardio-depress.  Drug interactions: Potent.eff.with other hypertens. /meds.with
       centr.-act.antihypertens. agents, ren.decompensat., monit.pulse rate   Ca chann.blocks.  hypotens.as S/E, digox. steady state trough conc.incr.in hypertens.,
       & indiv.pt.respons.in CCF pts.with digoxin, discont. clonidine sev.days   Side effects: Floppy inft.syndr.if giv.to mothers dur.labour/shortly   incr. syst.avail.with cimetidine, reduc.syst.avail.with rifampicin, poss.
       aft.β-block withdr.if giv. concurr., pre-exist.sod.deplet.esp.in ren.art.   bef.birth, postur.hypotens., bradycard., exacerbat.of periph.vasc.  incr.effs.of insul./oral hypoglycaem., poss.incr.lev.with alcoh./ hydrala-
       stenos., ang.pect.exacerbat.in ischaem.heart dis. on abrupt withdr.  dis., Raynauds phenom., periph.gangr.precipit., heartblock precipit.   zine, synergist.eff.with diltiazem, poss. hypotens./ sev.bradycard.with
       Drug interactions: NSAID reduc.antihypertens. effs., attenuat.  in pts.with underly.card.disords., chest pain, oed., syncope, bron-  meds.lead.to catecholamine deplet./adrenerg.block.agents., poss.
       of refl.tachycard./incr.hypotens.risk with anaesthet.agents, AV-  choconstrict./dyspn., in asthma, bronchit.& chron.pulm.dis.pts., GI   dimin.eff.with beta-adrenorecept.stimul. agents, revers.eff.with
       conduct.time incr./ heart rate reduct.with digoxin, reduc.eff.with   disturbs., hepat. inj., fatig., stuffy nose, fev., weight gain, impot.,   alpha-adrenocept.stimul. agents/ agents with both alpha & beta-
       beta-sympathomimets., poss.incr K -loss.with K -wast. agents.,   reduc.libido, haematur., urine retent., ren.funct.deteriorat.in CCF   adrenocept. stimul.propert., poss.incr.AV conduct. time/neg.inotrop.
                           +
                      +
       haemolys.with methyldopa, incr.eff.of uric acid low.agents, reduc.   pts., hypoglycaem., musc.weakn., myopathy incl.musc. cramps,   eff.with myocard. depress. agents incl.anti-arrythm.
       hydrochlorothiaz.absorpt. with cholestyramine/colestipol, incr.  neuropsychiatr.& CNS effs., paraesthes., periph. neuropathy, bld.
       bradycard.risk with mefloquin, enhanc.hypotens.eff./hypertens. cri-  dyscras., allerg.skin reacts., revers.alopec., stomatit., induc./aggrav.   CARVETREND, Pharma Dynamics [PWR]
       sis risk with MAOI, reduc.antihypertens. eff. with corticoster., slight   psorias., ocul.effs., trans.hear.loss, early signs of hyperglycaem. mask.  Carvedilol
       half-life reduct.with rifampicin, periph.circul.disturbs.exacerbat.  in diab., sympt.of hyperthyroid. mask., repeat.challenge in pts.with   Indications: Essent.mild to mod.hypertens., adjunct in mild to mod.
       with ergotamine derivats., poss.incr.AV-conduct. time/ bradycard.  anaphylax. to antigen hist.  stable symptomat.HF of cardiomyopath. /ischaem.origin, adjunct.
       risk with parasympathomimet.agents, incr. syst.effs.with topic.β-  Special precautions: 1st contr.phaechromocyt. adeq.with alpha   in longt. ther. follow.uncomplic.MI with (L) ventric. dysfunct.(LVEF)
       blocks., incr. bld.gluc. low.eff.with antidiab.agents, poss.intens.  block.bef.init., adeq.clinic.contr.in CHF bef.init.ther.esp.if HF controll.  (S3) TABS, 37/7.1.3/0276, 0277, 0278
       Li cardiotox./ neurotox.effs.through Li excret.reduct., concom.   with digital., diurets. &/ACE inhibits., in HF eval.pt.for worsen. sympts.   704670-001: 6,25 mg, 30, R72,30
       use of centr.-act.antihypertens.agents poss. lead to furth.heart   bef.each incr.& treat accord., discont.48 hrs. bef.anaesthes., peri-op   704671-001: 12,5 mg, 30, R75,90
       rate reduct./card.output/ vasodilat., poss.extreme hypotens.& AV   per., ren.impairm., elderly, discont.grad., pt.to limit.activ.dur.withdr.   704672-001: 25 mg, 30, R96,90
       block with concom. IV verapamil, poss.incr.hypotens.risk/ furth.   per., Prinzmetal’s variant ang., pulse rate&lt;55 beats / min., poss.anti-  Dosage: Take aft.meals. Init.with low.dos.titrat. grad.upwards.
       ventr.pump funct.deteriorat.in HF pts.with concom. Ca antagon.of   till optim.eff.
       dihydropyridine type, neg. inotrop.eff.incr.& eff.on AV conduct.time   diab./insul.dos.reduct., contact lense wear.due to reduc.lacrimat., clo-  Essent.hypertens: Adults: Init:12,5 mg once dly. for 1st 2 days
                                     nidine transf., monit.CHF pts.at risk of ren.fail., monit.pts. with tend.
       poss. potent.with Class 1 antidysrhythm.agents, incr. hypotens.risk   incr.to 25 mg once dly. Concom. diuret. may assist in desir.respons.
       with other anti-hypertens.agents/ meds. with BP-low.potent., po-  to bronchosp.at init.& upward titrat., when terminat.both carvedilol   Elderly: 12,5 mg once dly. If inadeq.it may be titrat. at 14 day interv.
                                     & clonidine tog. withdr.carvedilol sev.days bef.grad.decr.clonidine,
       tent.eff.on AV conduct. time with Class-111 antidysrhythm. agents,   up to 25 mg once dly/in div. dos.
       cert.anti-dysrhythm.agents poss.induc. torsade de pointes.  monit.digox.lev.when dos.chang., caref.contr.with digitalis.of pts.  Symptom.CHF: Admin.with food. Indiv. Init. 3,125 mg 2xdly at least
                                     receiv. longt.ß-block. agents if CCF poss.develop.
       ZIAK, (Biopharma Div) Merck   Drug interactions: NSAID’s antagon.hypotens. eff., potent.eff.of   x14 days. If toler.may be incr.at not less than 14 day interv.to 6,25
       Bisoprolol fumarate 2,5/5/10  mg hydrochlorothiazide   cert.anti-diabet.agents, potent. of AV conduct.time with myocard.de-  mg 2xdly, foll. by 12,5 mg 2xdly & thereaft.25 mg 2xdly. Max. 25 mg
       6,25/6,25/6,25 mg             press.agents incl.cert.anti-arrhythm., enzyme inhibit.aff. metabol., hy-  2xdly in pts.&lt; 85 kg & 50 mg 2xdly in those &gt;85 kg.
       Indications: Hypertens.       potens.& sev.bradycard.with reserpine / meds.depl.catecholamine &   (L) Ventric.dysfunct.foll.uncomplic.ac.MI: Indiv. Init.treatm.
       (S3) TABS. 31/7.1.3/0455, 0456, 0457.  adrenerg.neurone block.agents, dimin.eff.with ß-adrenorecept. stimu-  when pt. haemodynamic.stab.& fluid retent.minim. Pt.to have receiv.
       840300-018: 2,5/6,25 mg, 30, R184,54  lat. agents, hypotens.eff.revers.& periph. vasoconstrict. eff.enhanc.by   ACE inhib. x48 hrs.at stab.dos.at least dur.preced.24 hrs. Start. treatm.
       840319-002: 5/6,25 mg, 30, R184,54  a-adrenorecept. stimul. agents., decr.syst.availabil.with rifampicin,   betw.day 3-21 post MI. Init.recomm. dos: 6,25 mg. Keep und.close
       852929-005: 10/6,25 mg, 30, R184,54  incr.syst.bioavailabil.with cimetidine, hydralazine & alcoh.incr.plasma   supervis.x 3 hrs. Subseq. dos.if 1st dos.well toler. Incr.to 6,25 mg 2x
       Dosage: Init: 2,5 mg/6,25 mg once dly. Subseq. dos.adjust.to max.   conc., poss.life-threat. interacts. with phenothiazine & cert.anti-ar-  dly X3-10 days. Reduc.dos.to 3,125 mg 2x/day if intol.devel.esp.brady-
       10 mg/6,25 mg once dly.       rhythm., poss.potent.of antihypertens./meds.that have hypotens.eff.  card.(ie&lt;50 bpm)/syst.BP&lt; 80 mmHg or fluid retent. Discont.treatm.if
       Contraindications: Sulphonamide hypersens., uncontr.card.fail.  not well toler. Incr.again to 6,25 mg 2xdly aft.3-10 days if well toler.
       excl.that due to hypertroph. obstruct. cardiomyopathy, pregn.& lac-  CARVEDILOL UNICORN, Unicorn [N/P/S in C in only    Subseq.up-titrat: If 6,25 mg 2xdly if well toler. incr. at 3-10 day in-
       tat., metabol. acidos., sinus bradycard., 2nd & 3rd degr. heart block,   certain sports]  terv.to 12,5 mg 2xdly then 25 mg 2xdly. Maint: max.tol.dos. Max.
       ren.insuff., diab.nephropathy, childr.  Carvedilol         recomm.dos: 25 mg 2xdly.irrespect.of bm.
       Side effects: Heart fail./block, other CV eff., bronchosp., fatig., cold   Indications: Mild to mod.essent.hypertens., mild to mod.stable   Contraindications: Bronch.asthma/chron. obstruct. pulm.dis., sev.
       extrem., CNS eff., paraesthes., periph.neuropathy & myopathies, GI   symptomat.HF of ischaem./ cardiomyopath.origin as adjunct.to std.  bradycard., sick-sinus syndr. incl.sino-artrial block, 2nd/3rd degr. atrio-
       disturbs., hypersens.reacts., skin rash, prurit., rev. alopec., haema-  ther.incl. pts.not tol.to ACE inhibits.& pts.on or not on digital.ther.  ventric. block, unstable HF, New York Heart Assoc. class IV decom-
       tolog.reacts., hyperglycaem.& glycosur.in diab.& other suscept.indiv.,   (S3) TABS, 37/7.1.3/0279, 0280, 0281  pen.HF requir.IV inotrop. support,cardiogen.shock, clinic.manifest liv.
       hyperuricaem., precip.gout attacks, electrol.imbal., photosens., postur.  716742-001: 6,25 mg, 30, R72,33  impairm., sev.hypotens., safety in childr.not est., concom.Ca antagon.
       hypotens., impot., yellow vis., floppy inft.syndr.if admin.shortly bef.  716743-001: 12,5 mg, 30, R74,40  esp.verapamil in disturb.heart funct.
       birth/dur. labour, may mask sympts of hypothyroid.  716744-001: 25 mg, 30, R96,60  Side effects: Thrombocytopen., hypercholesterolaem., leucopen.,
       Special precautions: Imp.hepat./ren.funct., grad. withdr., ischaem.  Dosage: Take aft.meals. Init.low.dos. grad.titrat. until.optim.eff.  reduc.periph. circulat., Raynauds, intermitt.claudicat.sympt. exacer-
       heart dis., concom.class I antidysrhythmic agents & inhibit.of AV con-  achiev.  bat., hyperglycaem.in diab., latent diab. poss. evid./exist.diab.exac-
       duct., clonidine transf., hypoglycaem., bronchosp. asthma, obstruct.  Essent.hypertens: Adults: Init: 12,5 mg once dly.for first 2 days.incr.  erbat., asthma/dyspn.in predispos. pts, flu-like sympts., stuffy nose,
       airway dis., anaesth./surg., periop peroid, concom.verapamil.in pts.  to 25 mg dly.thereaft. Combin.with a diuret.may assist in desir. clinic.   wheez., weight incr., dizzin., headache, fatig., CNS effs., vis. abnorm.,
       with imp. ventric.funct.& to pts.with conduct.abnormalit., concom. IV   respos. Elderly: Init.12,5 mg once dly. If necess. incr.dos. at 14 day   reduc.lacrimat., eye irrit., vis. disturbs., card.disords., sex.impot., GI
       admin.with Ca antagon.& antiarrythm. not recomm.  interv.up to 25 mg once dly or in div.dos.  disturbs., dry mouth, skin reacts.incl.lichen planus-like reacts./ allerg.
       Drug interactions: Concom.hypoglycaem.agents, phenothiaz. &   Symptom.CHF: Admin.with food. Indiv.& clos. monit.by practit.  exanthema, ac.ren.fail.& ren.abnorm., micturit. disturbs., bradycard.,
       various anti-arrythm.agents poss.life threaten., effs.of hypoglycaem.  exper.in HF managem., dur.up-titr. Stabil.concom.digital./diurets./  legs/genit./periph. oed., extremit.pain, hypotens., periph.hypervol.,
       agents & myocard. depress. enhanc., eff.antagon.by ß-adrenocept.   ACE inhibits. bef.init.ther. Init: 3,125 mg 2x dly for at least 14 days.   gener.fluid overload., syncope, ang.pect., progress. of HF, AV-block/
       stimulat. agents, alpha adrenocept.stimul.may danger. revers.hypo-  If toler.incr.dos.at interv.of not less than 14 days to 6,25 mg 2x/day.,   CF dur.dos.incr., postur.hypotens.
       tens.eff.& enhanc vasoconstrict. eff., effs.poss.enhanc.by adrenerg   12,5 mg 2x/day & then 25 mg 2x/day. Max.recomm.dos: less than   Warnings and special precautions: Monit.init. / dur. dos.
       neurone block.agents, half life short.by rifampicin, hypotens.eff.of   85 kg: 25 mg 2x/day. More than 85 kg: 50 mg 2x/day. Practit.to as-  adjustm., contr.CCF , 1st contr. phaeochromocyt.adeq.with alpha
       antihypertens.& CNS depress. enhanc., enhanc.eff.of neuroblock.  sess pt.for worsen. HF/ vasodilat. bef.dos.incr. Reinst.ther.as above   block., ren. impairm., not for use in obstruct.airway dis./ bron-
       agents, diminish. eff.of press.amines, hypokalaem.eff. incr. toxicat.  should treatm.be discont.for long.than 14 days.   chosp./ allerg.condits.involv.airways/ metabol. acidos./part.heart
       of digital.glycos., hypokalem.enhanc.by corticoster., corticotroph.&   Contra-indications: Bronch.asthma, chron. obstruct. pulm.dis., sev.  block/sinus bradycard., clonidine transf., pulse rate &lt;55 beats/min.,
       carbenoxolone.                bradycard.(&lt;50 bpm), sick-sinus syndr.incl.sino-artrial block, 2nd/3rd   grad. discont. in ischaem.heart dis., monit.ren.funct.in CHF dur.dos.
                                     degr. AV block, unstab.HF, New York Heart Assoc. class IV decompen.   adjustm., dos.of pts.on concom. digit./ diuret.&/ACE inhibit.to be
                                     HF requir.IV inotrop. support, cardiogen. shock, hepat.funct.impairm.,   stabilis. bef.init. ther., early ac.hypoglycaem.warn.S&S poss. en-
                                     sev. hypotens. (syst.BP &lt;85mmHg), safety in childr.not est., obstruct.
       7.3.4   Alpha- and beta-receptor  airway dis./bronchosp./allerg. condits. involv.airways, metabol.aci-  hanc./mask., not recomm.in COPD with bronchosp., consid.benef.
                                                                  vs.risk in pts.not requir. oral/ inhal. ther.for bronchosp.dis.& monit.
              blockers               dos., part. heart block, sinus bradycard., concom.Ca antagon. esp.  reg., thyrotoxicos. sympts.mask., Raynaud sympts. exacerb., cont.
                                     verapamil in disturb.heart funct., safety in pregn. not est., lactat.,
                                                                  lens., periph.vasc.dis, Prinzmetal’s ang./ ciclospor.monit.esp.when
                                     use in pts. undergo. anaesthes.not est.  init.ther, IV atrop.for vagal influenc.protect., anaesthes./maj. surg.,
       CARLOC, Cipla Medpro [PWR]    Side-effects: Bradycard., GI disturbs., leg/ genit./ periph./gen.oed.,   ser.hypersens.react.hist., pts.undergo. desensitisat., consid.benef.
       Carvedilol                    fluid overload, hypervolaem., pain in extremit., hypotens.also postur.,   vs. risk in psorias.hist. assoc. with β-blocks., monit.ECG/BP with
       Indications: Essent.mild to mod.hypertens., adjunct in mild to   AV block, card.fail.dur.dos.incr., syncope, ang.pect./HF progress., bld.  Ca-chann. blocks of verapamil/diltiazem type/other anti-dysrhythm.
       mod.stable symptomat.HF of ischaem/cardiomyopath.origin, oft.in   dyscras., hypercholesterolaem., reduc.periph.circulat., thyotoxicos.   meds., lact.intol., lactat., safety in pregn. not est., excret.in breast
       conjunct. with stand.ther.    sympt.may be mask., Raynaud’s phenom., sympt.exacerbat.of inter-  milk, discont.grad. esp. in pts.with concom.coron.heart dis., monit.
       (S3) TABS 37/7.1.3/0613, 34/7.1.3/0433, 0434  mit. claudicat., ser.transaminas.chang., hyperglycaem.in pre-exist.   digox. lev.when init./adjust./discont.carvedilol, elderly, incr.diuret.
       705459-001: 6,25 mg, 30, R71,56  diab.mellit., diab.mellit. exacerbat., latent diab.mellit.evid., asthma,   dos.if worsen.card.effs./fluid retent. occur dur.dos.incr., in HF eval.
       700168-001: 12,5 mg, 30, R75,90  dyspn., flu-like sympt., stuffy nose, wheez., vis. disturbs., reduc.lac-  pt for worsen. sympts.bef.each incr.& treat accord., if ther. discont.
       897117-006: 25 mg, 30, R96,90  rimat., ren.abnormal., ac.ren. fail., micturit. disturbs., skin reacts.incl.  long.than 2 wks.in HF init.from start. point, reduct.in diuret.dos.may
       Dosage: Hypertens: Adults: Init.6,25 mg 2xdly for 1-2 wks. Maint.  lichen planus-like reacts./allerg.exanthem., CNS effs., sex.impot.,   assist in managem. of vasodilat. sympts., do not incr.dos.until sympts.
       dos: 12,5 mg 2xdly or init. 12,5 mg dly for 2 days. Maint.dos: 25 mg dly.  weight incr., dry mouth.  of worsen.HF/vasodilat.are stabil.</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page129.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page125.html">125</a>&nbsp;&nbsp;&nbsp;<a href="page126.html">126</a>&nbsp;&nbsp;&nbsp;<a href="page127.html">127</a>&nbsp;&nbsp;&nbsp;<a href="page128.html">128</a>&nbsp;&nbsp;&nbsp;<a href="page129.html">129</a>&nbsp;&nbsp;&nbsp;<a href="page130.html">130</a>&nbsp;&nbsp;&nbsp;<a href="page131.html">131</a>&nbsp;&nbsp;&nbsp;<a href="page132.html">132</a>&nbsp;&nbsp;&nbsp;<a href="page133.html">133</a>&nbsp;&nbsp;&nbsp;<a href="page134.html">134</a>&nbsp;&nbsp;&nbsp;<a href="page135.html">135</a>
             </td>
             <td width="35%"><a href="page131.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page131.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
